Integrating supplementation in the management of patients with heart failure: an evidence-based review

References

• NIH [Internet)]. Complimentary, alternative, or integrative health: what’s in a name? [cited 2021 Mar]. https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name
   Google Scholar
• *Esmail N (2017 5 March 2021). Complementary and alternative medicine: use and public attitudes 1997, 2006, and 2016. Fraser Institute. https://www.fraserinstitute.org/sites/default/files/complementary-and-alternative-medicine-2017.pdf
   Google Scholar
• Schocken DD. When complementary and alternative medicine meets heart failure – a modest proposal. J Card Fail. 2018;24(3):202–203.
   PubMed Web of Science ®Google Scholar
• Langsjoen P, Folkers K, Lyson K, et al. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988;66(13):583–590.
   PubMedGoogle Scholar
• López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019;57:133–140.
   PubMed Web of Science ®Google Scholar
• Weber C, Bysted A, Hìlmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res. 1997;67(2):123–129.
   PubMed Web of Science ®Google Scholar
• *Mantle D, Dybring A. Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants (Basel). 2020;9(5):386.
   Google Scholar
• Greenberg S, Frishman W. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990;30:596–612.
   PubMed Web of Science ®Google Scholar
• Bhagavan H, Chopra R. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7:78.
   PubMed Web of Science ®Google Scholar
• Miles M. The uptake and distribution of coenzyme Q10. Mitochondion. 2007;7:72–75.
   PubMed Web of Science ®Google Scholar
• Bhagavan H, Coenzyme CR. Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006;40(5):445–448.
   PubMed Web of Science ®Google Scholar
• Zaki N. Strategies for oral delivery and mitochondrial targeting of CoQ10. Drug Deliv. 2016;23:1868–1881.
   PubMed Web of Science ®Google Scholar
• Sato Y, Mutoh H, Suzuki M, et al. Emulsification using highly hydrophilic surfactants improves the absorption of orally administered coenzyme Q10. Biol Pharm Bull. 2013;36:2012–2017.
   PubMed Web of Science ®Google Scholar
• Langsjoen P, Langsjoen A. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32:119–128.
   PubMed Web of Science ®Google Scholar
• Casagrande D, Waib P, Jordão Júnior A. Mechanisms of action and effects of the administration of coenzyme Q10 on metabolic syndrome. J Nutr Intermed Metab. 2018;13:26–32.
   Google Scholar
• Sugiyama S, Kitazawa M, Ozawa T, et al. Anti-oxidative effective of coenzyme Q10. Experientia. 1980;36(8):1002–1003.
   PubMedGoogle Scholar
• Moriso C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71:134–136.
   Google Scholar
• Folkers K, Littarru G, Ho L, et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int J Vitam Res. 1970;40:380–390.
   Google Scholar
• Folkers K, Watanabe T, Kaji M. Critique of coenzyme Q in biochemical and biomedical research and of ten years of clinical research on cardiovascular disease. J Mol Med 1977;2:431–460.
   Web of Science ®Google Scholar
• Mortensen S, Kondrup J, Folkers K. Myocardial deficiency of coenzyme Q10 and carnitine in cardiomyopathy: biochemical rationale for concomitant coenzyme Q10 and carnitine supplementation. Vol. 6. Amsterdam: Elsevier Academic Press; 1991. p. 269–281.
   Google Scholar
• Mantle D. Coenzyme Q10 and cardiovascular disease: an overview. Br J Cardiol. 2015;22:160.
   Google Scholar
• Morisco C, Nappi L, Argenziano D, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Aspects Med. 1994;15(1):155–163.
   Google Scholar
• Baggio E, Gandini R, Plancher A, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol Aspects Med. 1994;15:287–294.
   Web of Science ®Google Scholar
• Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 study group. J Card Fail. 1995;1(2):101–107.
   PubMedGoogle Scholar
• Watson P, Scalia G, Galbraith A, et al. Lack of effect of coenzyme Q of left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999;33(6):1549–1552.
   PubMed Web of Science ®Google Scholar
• Munkholm H, Hansen H, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2–4):285–289.
   PubMed Web of Science ®Google Scholar
• Sacher H, Sacher M, Landae S, et al. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther. 1997;4(2):66–72.
   PubMedGoogle Scholar
• Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Inter Med. 2000;132(8):636–640.
   PubMed Web of Science ®Google Scholar
• Sobirin M, Herry A, Sofia S, et al. Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discov Ther. 2019;13(1):38–46.
   PubMed Web of Science ®Google Scholar
• Belardinelli R, Muçai A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors. 2005;25(1–4):137–145.
   PubMed Web of Science ®Google Scholar
• Mortensen S, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from Q-SYMBIO: a randomized double-blind trial. J Am Coll Cardiol. 2014;2(6):641–649.
   Google Scholar
• Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422–2435.
   PubMed Web of Science ®Google Scholar
• Roe C, Ding J. Mitochondrial fatty acid oxidation disorders: the metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2297–2326.
   Google Scholar
• Housten S, Wanders R. A general introduction to the biochemistry of mitochondrial fatty acid β -oxidation. J Inherit Metab Dis. 2010;33(5):469–477.
   PubMed Web of Science ®Google Scholar
• Drosatos K, Schulze P. Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep. 2013;10(2):109–121.
   PubMedGoogle Scholar
• Vaz F, Wanders R. Carnitine biosynthesis in mammals. Biochem J. 2002;361(\(Pt 3)):417–429.
   PubMedGoogle Scholar
• Longo N, Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;36(2):77–85.
   Google Scholar
• *Rebouche C. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033(1):30–41.
   PubMedGoogle Scholar
• Mendelson S. Acetylcarnitine. Science Direct [Internet]. 2008. [cited 2021 May]. https://www.sciencedirect.com/topics/neuroscience/acetylcarnitine
   Google Scholar
• The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure, Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J. 1999;20(1):70–76 https://academic.oup.com/eurheartj/article/20/1/70/518106.
   PubMed Web of Science ®Google Scholar
• Paulson D, Traxler J, Schmidt M, et al. Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport and fatty acid oxidation. Cardiovasc Res. 1986;20(7):538–541.
   Web of Science ®Google Scholar
• Hülsmann W. Biochemical profile of propionyl-L-carnitine. Cardiovasc Drugs Ther. 1991;5(1):7–10.
   PubMedGoogle Scholar
• Siliprandi N, Di Lisa F, Menabò R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991;5(1)11–15.
   PubMedGoogle Scholar
• Tripp M, Shug A. Plasma Carnitine concentrations in cardiomyopathy patients. Biochem Med 1984;32:199–206. 2
   PubMedGoogle Scholar
• Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291–299. 3
   PubMed Web of Science ®Google Scholar
• Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2):120–123.
   Web of Science ®Google Scholar
• Serati A, Motamedi M, Emami S, et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvements in diastolic function and symptoms. Cardiology. 2010;116(3):178–182.
   PubMed Web of Science ®Google Scholar
• Tassell M, Kingston R, Gilroy D, et al. Hawthorn (crateagus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev 2010;4(7):32–41.
   PubMedGoogle Scholar
• *Holubarsch C, Colucci W, Meinertz T, et al., Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive health failure (SPICE) – rationale, study design and study protocol. Eur J Heart Fail. 2(4): 431–437. 2000.
   PubMed Web of Science ®Google Scholar
• Holubarsch C, Colucci W, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail. 2008;10(12):1255–1263.
   PubMed Web of Science ®Google Scholar
• Dalli E, Colomer E, Tormos M, et al. Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial. Phytomedicine. 2011;18(8–9):769–775.
   PubMed Web of Science ®Google Scholar
• Guo C, Yang J, Wei J, et al. Antioxidant activities of peel, pulp and seed fractions of common fruits as determined by FRAP assay. Nutr Res. 2003;23(12):1719–1726.
   Web of Science ®Google Scholar
• Yoo K, Lee C, Lee H, et al. Relative antioxidant and cytoprotective activities of common herbs. Food Chem. 2008;106(3):929–936.
   Web of Science ®Google Scholar
• Ljubuncic P, Portnaya I, Cogan U, et al. Antioxidant activity of Crataegus aronia aqueous extract used in traditional Arab medicine in Israel. J Ethnopharmacol. 2005;101(1–3):153–161.
   PubMed Web of Science ®Google Scholar
• Cui T, Nakamura K, Tian S, et al. Polyphenolic content and physiological activities in Chinese hawthorn extracts. Biosci Biotechnol Biochem. 2006;70(12):2948–2956.
   PubMed Web of Science ®Google Scholar
• Brixius K, Willms S, Napp A, et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther. 2006;20(3):177–184.
   PubMed Web of Science ®Google Scholar
• Ling S, Nheu L, Dai A, et al. Effects of four medicinal herbs on human vascular endothelial cells in culture. Int J Cardiol. 2008;128(3):350–358.
   PubMed Web of Science ®Google Scholar
• Fan C, Yan J, Qian Y, et al. Regulation of lipoprotein lipase expression by effect of hawthorn flavonoids on peroxisome proliferator response element pathway. J Pharmacol Sci. 2006;100(1):51–58.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Walter H, Huang Y, et al. Hypocholesterolemic activity of hawthorn fruit is mediated by regulation of cholesterol-7α-hydroxylase and acyl CoA: cholesterol acyltransferase. Food Res Int. 2002;35(9):885–891.
   Web of Science ®Google Scholar
• Wojdyto A, Oszmiański J. Influence of polyphenols isolated from scutellaria baicalensis georgi and Crataegus oxyacantha on the oxidative stability of cholesterol in butter stored in various conditions. Eur Food Res Technol. 2007;224:635–642. 5
   Web of Science ®Google Scholar
• Schüssler M, Hölzl J, Fricke U. Myocardiacl effects of flavonoids from Crataegus species. Arzneimittelforschung. 1995;45(8):842–845.
   PubMed Web of Science ®Google Scholar
• Long S, Carey R, Crofoot K, et al. Effect of hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine. 2006;13(9–10):643–650.
   PubMed Web of Science ®Google Scholar
• Tauchert M. Efficacy and safety of Crataegus extract WS1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J. 2002;143(5):910–915.
   PubMed Web of Science ®Google Scholar
• Zick S, Vautaw B, Gillespie B, et al. Hawthorn extract randomized blinded chronic heart failure (HERBCHF) trial. Eur J Heart Fail. 2009;11(10):990–999.
   PubMed Web of Science ®Google Scholar
• Degenring F, Suter A, Weber M, et al. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine. 2003;10(5):363–369.
   PubMed Web of Science ®Google Scholar
• Elin R. Magnesium metabolism in health and disease. Dis Mon. 1988;34(4):161–218.
   PubMed Web of Science ®Google Scholar
• Wacker W. Magnesium and Man. Cambridge (MA): Harvard University Press; 1980. p. 1–184.
   Google Scholar
• Elin R. Assessment of magnesium status for diagnosis and therapy. Magnes Res. 2010;23(4):194–198.
   PubMed Web of Science ®Google Scholar
• Alfrey A, Miller N. Bone magnesium pools in uremia. J Clin Invest. 1973;52(12):3019–3027.
   PubMed Web of Science ®Google Scholar
• Maguire M, Cowan J. Magnesium chemistry and biochemistry. Biometals. 2002;15(3):203–210.
   PubMed Web of Science ®Google Scholar
• *Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i13–i14.
   PubMedGoogle Scholar
• Marx A, Neutra R. Magnesium in drinking water and ischemic heart disease. Epidemiol Rev. 1997;19(2):258–272.
   PubMed Web of Science ®Google Scholar
• Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J. 2001;94(12):1195–1201.
   PubMed Web of Science ®Google Scholar
• Ford E, Mokdad A. Dietary magnesium intake in a national sample of US adults. J Nutr. 2003;133(9):2879–2882.
   PubMed Web of Science ®Google Scholar
• Aikawa J. Magnesium: its biological significance. Boca Raton (FL): CRC Press; 1981.
   Google Scholar
• Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003;24(2):47–66.
   PubMedGoogle Scholar
• Saris N, Mervaala E, Karppanen H, et al. Magnesium. An update on physiological, clinical and analytic aspects. Clin Chim Acta. 2000;294(1–2):1–26.
   PubMed Web of Science ®Google Scholar
• Kayne L, Lee D. Intestinal magnesium absorption. Miner Electrolyte Metab. 1993;19(4–5):210–217.
   PubMedGoogle Scholar
• Fawcett W, Haxby E, Male D. Magnesium: physiology and pharmacology. Br J Anaesth. 1999;83(2):302–320.
   PubMed Web of Science ®Google Scholar
• Touyz R. Magnesium in clinical medicine. Front Biosci. 2004;9(1–3):1278–1293.
   PubMedGoogle Scholar
• Almoznino-Sarafian D, Berman S, Shteinshnaider M, et al. Magnesium and c-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr 2007;46:230–237.
   PubMed Web of Science ®Google Scholar
• Stepura O, Martynow A. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol. 2009;131(2):293–295.
   PubMed Web of Science ®Google Scholar
• Fuentes J, Salmon A, Silver M. Acute and chronic oral magnesium supplementation: effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. Congest Heart Fail. 2006;12(1):9–13.
   PubMedGoogle Scholar
• Bashir Y, Sneddon J, Staunton H, et al. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1993;72(15):1156–1162.
   PubMed Web of Science ®Google Scholar
• Guerrera M, Volpe S, Mao J. Therapeutic uses of magnesium. Am Fam Physician. 2009;80(2):157–162.
   PubMed Web of Science ®Google Scholar
• Nair R, Vitamin MA. D: the “sunshine” vitamin. J Pharmacol Pharmacother. 2012;3(2):118–126.
   PubMedGoogle Scholar
• Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006;260(3):245–254.
   PubMed Web of Science ®Google Scholar
• Thomas M, Lloyd-Jones D, Thadhani R, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777–783.
   PubMed Web of Science ®Google Scholar
• Dusso A, Brown A, Vitamin SE. D. Am J Physiol Renal Physiol. 2005;289(1):F8–28.
   PubMed Web of Science ®Google Scholar
• Harvard School of Public Health Nutrition Science Vitamin D. [cited 2021 May]. https://www.hsph.harvard.edu/nutritionsource/vitamin-d/
   Google Scholar
• Chlebowski R, Johnson K, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100(22):1581–1591.
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon R, Vieth R, Azad A, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006;66(20):10213–10219.
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon R, Hayes R, Horst R, et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 2009;69(4):1439–1447.
   PubMed Web of Science ®Google Scholar
• *Wang T, Pencina M, Booth S, et al., Vitamin D deficiency and risk of cardiovascular disease. Circulation. 117(4): 503–511. 2008.
   PubMed Web of Science ®Google Scholar
• Lappe J, Travers-Gustafson D, Davies K, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–1591.
   PubMed Web of Science ®Google Scholar
• Greene-Finestone L, Berger C, De Groh M, et al. 25-hydroxyvitamin D in Canadian adults: biological, environmental, and behavioural correlates. Osteoporos Int. 2011;22(5):1389–1399.
   PubMed Web of Science ®Google Scholar
• Witte K, Byrom R, Gierula J, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. J Am Coll Cardiol. 2016;67(22):2593–2603.
   PubMed Web of Science ®Google Scholar
• Witham M, Crighton L, Gillespie N, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail. 2010;3(2):195–201.
   PubMed Web of Science ®Google Scholar
• Dalbeni A, Scaturro G, Degan M, et al. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nut Metab Cardiovasc Dis. 2014;24(8)861–868.
   PubMed Web of Science ®Google Scholar
• Zittermann A, Ernst J, Prokop S, et al. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. Eur Heart J. 2017;38(29):2279–2286.
   PubMed Web of Science ®Google Scholar
• Moretti H, Colucci V, Berry B. Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. BMC Cardiovasc Disord. 2017;17(1):274.
   PubMedGoogle Scholar
• Navarro-Valverde C, Sosa-Henríquez M, Alhambra-Expósito M, et al. Vitamin D3 and calcidiol are not equipotent. J Steroid Biochem Mol Biol. 2016;164:205–208.
   PubMed Web of Science ®Google Scholar
• Heart and Stroke. [Internet]. Canada. 2017. [cited May 2021] https://www.heartandstroke.ca/-/media/pdf-files/Canada/2017-heart-month/heartandstroke-reportonhealth-2016.ashx?la=en
   Google Scholar
• Grotto D, Zied E. The standard American diet and its relationship to the health status of americans. Nutr Clin Pract. 2010;25(6):603–612.
   PubMed Web of Science ®Google Scholar